| Name | Title | Contact Details |
|---|---|---|
Anavelys Ortiz-Suarez |
Associate General Counsel | Profile |
Anavelys Ortiz--Suarez |
Associate General Counsel | Profile |
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the healthcare and medical
Peer Direct is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
FYZICAL is the world`s fastest growing healthcare franchise, leading the charge to transform healthcare from one of “sick care” to “well care” by providing services focused on quality outcomes, total well-being, and prevention. FYZICAL provides business instruments allowing you to run your business more successfully and more profitably, immediately. Using a Nobel Prize winning formula, elite PTs, medical professionals, and business experts have created an innovative new business model which not only sets the standard for excellence in patient care, but also allows you to become the dominant provider of health care services in your community and secure a successful future. FYZICAL is effecting real change in healthcare by servicing a major unmet need in the patient population allowing independent business owners (financiers, PTs, Audiologists and Otolaryngologists) to experience emotional and financial rewards in the process.
Amplyx Pharmaceuticals, Inc. is a preclinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The resulting, new therapeutic creates a more targeted molecule with the goal of improving treatment outcomes and improving compliance with treatment regimens. Our initial development areas are in oncology and infectious disease.
Pathalys Pharma, Inc. is a private, late-stage clinical biopharmaceutical company committed to the development of multiple advanced therapeutics that address unmet needs in the management of end stage kidney disease (ESKD). Pathalys` initial asset is upacicalcet, a novel calcimimetic with the potential to improve the treatment of SHPT in hemodialysis patients. Beyond upacicalcet, Pathalys continues to identify other high priority needs and potential solutions for patients with ESKD. Pathalys is headquartered in Research Triangle Park, North Carolina.